Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid,...
- Mechanism
- Curator reviewed
AZD2563 selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, AZD2563 binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process.
- Primary indication
- For the treatment of gram-positive infections, including multiresistant strains.Curator reviewed
- Formula / weight
- C21H21F2N3O7 · 465.41 g/mol (avg)
- Code names
- AZD-2563 · AZD-5847
Resolves to
HBUJYEUPIIJJOS-PBHICJAKSA-NSMILESOC[C@H](O)C(=O)N1CCC(=CC1)C1=C(F)C=C(C=C1F)N1C[C@H](COC2=NOC=C2)OC1=OWhat you can answer from here — as of February 21, 2021
Which drugs share a target with Posizolid, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account